The OJC Episode 34: A Manifesto for Good Trial Design

Pinterest LinkedIn Tumblr +

The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 34 in our series The Oncology Journal Club.

This week we have another great episode for you in our usual format. Craig Underhill gets us started by talking us through primary tumour resection plus chemotherapy versus chemotherapy alone for metastatic colorectal cancer patients.

Hans Prenen gets stuck into the use of tipifarnib in head and neck squamous cell carcinoma with HRAS mutations and Eva Segelov continues to guide us through what she calls a ‘manifesto for good study design’ – a key paper from our friend Bishal Gyawali, addressing biases in study design that distort the appraisal of clinical benefit.

About The Oncology Journal Club:

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.

With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.

The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.

This Week’s Papers:

  1. Kanemitsu Y, et al; JCOG Colorectal Cancer Study Group. Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial. J Clin Oncol. 2021 Apr 1;39(10):1098-1107. doi: 10.1200/JCO.20.02447. Epub 2021 Feb 9. Access online here.
  2. Ho AL, et al. Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. J Clin Oncol. 2021 Mar 22:JCO2002903. doi: 10.1200/JCO.20.02903. Epub ahead of print. Access online here. 
  3. Gyawali B, et al. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. ESMO Open. 2021 Apr 19;6(3):100117. doi: 10.1016/j.esmoop.2021.100117. Epub ahead of print. Access online here.

This Week’s Quick Bites:

  1. Rahib L, et al. Estimated Projection of US Cancer Incidence and Death to 2040. JAMA Netw Open. 2021;4(4):e214708. Access online here.
  2. Cheng, M.L., et al. Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC. JCO Precision Oncology no. 5 (2021) 726-732. Published online April 27, 2021. Access online here.
  3. Conroy T, et al; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Apr 13:S1470-2045(21)00079-6. doi: 10.1016/S1470-2045(21)00079-6. Epub ahead of print. Access online here.
  4. Eyck BM, et al; CROSS Study Group. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin Oncol. 2021 Apr 23:JCO2003614. doi: 10.1200/JCO.20.03614. Epub ahead of print. Access online here.
  5. Probst, H. et al. The patient experience of radiotherapy for breast cancer: A qualitative investigation as part of the SuPPORT 4 All study. Radiography, Volume 27, Issue 2, 352 – 359. Access online here.
  6. Harrison, M., et al. Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer. 25 March 2021. Access online here.
  7. Leone, R.D. et al. Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy. Cancer Immunology Research. Published March 2021. Access online here.

Twitter Account of the Week:


Other Episodes Mentioned:

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

You can find Eva on Twitter here: @profevasegelov

Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

You can find Craig on Twitter here: @CraigUnderhill

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.

You can find Hans on Twitter here: @HPrenen


Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen and Graham Knowles.

Connect with us on Twitter @OncologyNewsAus


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.